A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity

Summary

The main purpose of this study is to measure the safety and efficacy of tirzepatide in adult participants in India who have type 2 diabetes or who have obesity or overweight without type 2 diabetes. Participation in the study will last about 46 weeks.

Eligibility

Inclusion Criteria:

Participants with Type 2 Diabetes:

* Have had type 2 diabetes for at least one year
* Insulin naive
* Have HbA1c ≥7.5% and ≤10% at screening
* Have body mass index (BMI) ≥23 kilograms per square meter (kg/m2)

Participants with Obesity or Overweight without Type 2 Diabetes:

* Have a BMI

  * Greater than or equal to 30 kg/m2 OR
  * Greater than or equal to 27 kg/m2 AND previously diagnosed with at least one of the following weight-related comorbidities: high blood pressure, lipid disorder, obstructive sleep apnea, heart disease

Exclusion Criteria:

Participants with Type 2 Diabetes:

* Have type 1 diabetes
* Have had any of the following heart conditions within 6 months prior to screening:

  * heart attack
  * stroke
  * hospitalization due to heart failure
* Have New York Heart Association Functional Classification Class III or IV congestive heart failure (CHF)
* Have type 2 diabetes along with morbid obesity and being considered for bariatric surgery or any other procedure intended for weight loss

Participants with Obesity or Overweight without Type 2 Diabetes:

* Have type 1 diabetes or type 2 diabetes
* Have a self-reported change in body weight greater than 5 kilograms (kg) (11 pounds) within 3 months prior to screening
* Have a prior or planned surgical treatment for obesity
* Have had any of the following heart conditions within 6 months prior to screening:

  * heart attack
  * stroke
  * hospitalization due to heart failure
* Have New York Heart Association Functional Classification Class III or IV CHF
* Have taken any medications or alternative remedies for weight loss within 3 months prior to screening

Conditions4

Interventions1

Related trials

• A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar — McGill University Health Centre/Research Institute of the McGill University Health Centre
• A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus — Arrowhead Pharmaceuticals
• A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK) — Eli Lilly and Company
• A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults — Cambridge University Hospitals NHS Foundation Trust
• Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD — Cardenal Herrera University
• Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis — NHS Greater Glasgow and Clyde
• Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes — Nanjing First Hospital, Nanjing Medical University
• Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes — Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Browse More Trials